Taltz® (ixekizumab) – New indication

- On December 1, 2017, Eli Lilly announced the FDA approval of Taltz (ixekizumab), for the treatment of adult patients with active psoriatic arthritis (PsA).
    - Taltz is also indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
- PsA is a chronic, progressive and painful form of inflammatory arthritis. Approximately 1.6 million Americans have the disease.
- The safety and efficacy of Taltz in PsA were demonstrated in two placebo-controlled studies (SPIRIT-P1 and SPIRIT-P2) in 679 adult patients. SPIRIT-P1 enrolled patients who had not received a biologic disease-modifying anti-rheumatic drug (DMARD), and SPIRIT-P2 enrolled patients who had failed one or two tumor necrosis factor inhibitors. The primary endpoint was the percentage of patients achieving an American College of Rheumatology (ACR) 20 response at week 24.
    - In SPIRIT-P1, the primary endpoint was achieved in 58% of Taltz-treated patients vs. 30% of placebo-treated patients (Difference: 28 [95% CI: 15, 41]).
    - In SPIRIT-P2, the primary endpoint was achieved in 53% of Taltz-treated patients vs. 20% of placebo-treated patients (Difference: 34 [95% CI: 22, 45]).
- The recommended dose of Taltz for the treatment of adults with PsA is 160 mg by subcutaneous injection (two 80 mg injections) at week 0, followed by 80 mg every 4 weeks.
    - Taltz may be administered alone or in combination with a conventional DMARD (eg, methotrexate).
    - For PsA patients with coexistent moderate-to-severe PsO, use the dosing regimen for PsO.
    - Consult the Taltz drug label for the dosing in PsO.